The signature of PSG3, PSG7, and PSG8 was also found to show a statistically significant survival difference (P = .0138) between the PSG+ and PSG− groups in uterine cancer and borderline significance (P = .0746) in female kidney cancer patients. This evidence concerns the gene PSG5 and uterine cancer.